Philip Thompson is a Professor of Medicinal Chemistry at the Monash Institute of Pharmaceutical Sciences. Research in the Thompson group seeks to answer questions about the molecular pharmacology of organic molecules, and also to develop new tools to help answer those questions. In peptide science, we attempt to develop peptide chemistry to yield compounds with improved utility. Our current targets of interest are antibacterial cyclic lipopeptides, peptide GPCRs, and protease inhibitors. The group has also had a long-term focus on the mechanisms underpinning PI3K isoform inhibitor selectivity, leading to novel inhibitors under investigation as potential therapeutics to treat cancer or thrombosis. More recently, the group has investigated the medicinal chemistry of emerging epigenetic targets and targeted protein degradation.